Amyotrophic Lateral Sclerosis has traditionally been viewed as a relentlessly progressive condition — one that steadily affects the nerve cells controlling movement.
For many years, the focus has been on slowing progression rather than changing the biology of the disease.
But in the past decade, something remarkable has happened.
Advances in regenerative medicine, neuroprotection, and non-invasive neurostimulation have started to shift scientific thinking. Instead of simply trying to slow ALS, researchers are now exploring ways to:
Two major technologies stand at the frontier:
Together, they represent a new vision of ALS care — one based on biology, repair, and neuroplasticity.
ALS involves damage to motor neurons in the brain and spinal cord. As these cells weaken, muscles lose their signals and gradually atrophy. The biological drivers include:
STEM Cells do not reverse ALS, but they seek to slow progression, protect neurons, and improve function.
STEM Cells offer multiple therapeutic advantages:
(such as NSI-566, used in Phase I/II trials)
(still experimental)
1. Neural Stem Cell Trial (NSI-566) — Glass et al., 2016–2021
In these groundbreaking trials:
Most importantly: The treatment was safe and showed signs of slowing functional decline.
2. Autologous Bone-Marrow MSC Trials (Satti, Karussis, Blanquer)
These studies consistently show:
3. BrainStorm NurOwn® Trials (Phase II and III)
NurOwn is an MSC-based therapy designed to release high levels of neurotrophic (healing) factors.
Findings include:
Although the Phase III trial did not meet FDA approval criteria, many researchers continue to view NurOwn as a scientifically promising approach that warrants further study.
4. Mesenchymal Stem Cell (MSC) Trials — Petrou et al., 2016–2020
This group performed repeated intrathecal MSC injections.
Results showed:
Patients receiving higher doses often showed better stabilization compared to controls.
tDCS uses mild electrical currents to stimulate brain areas controlling movement.
Studies show:
Because ALS involves degeneration of upper motor neurons, tDCS may help “reawaken” weakened circuits.
TPS uses focused acoustic pulses to activate deep neural networks.
Early results from other neurodegenerative conditions (Alzheimer’s, Parkinson’s) show:
Although TPS in ALS is still emerging, researchers believe it may:
Its safety and non-invasiveness make it an attractive option for integrative ALS care.
The vagus nerve regulates:
Non-invasive vagus stimulation (taVNS):
In ALS, where inflammation accelerates neuron loss, VNS may offer protective effects.
For ALS – a disease affecting both biology and neural pathways – this combined strategy may be especially impactful.
Even though ALS remains a serious condition, research in recent years has opened a door that was once firmly closed.
We now know:
And with the combination of stem-cell therapy, neuromodulation, and specialized rehabilitation, many patients experience meaningful changes that were once thought impossible.
The future of ALS treatment is not just about slowing decline – it is about supporting life, function, connection, and hope.
Families often notice a “softening” of the disease’s rapid progression. While results vary, patients receiving regenerative or neuromodulation therapies often report:
STEM Cell Vienna delivers cutting-edge regenerative treatments with a guaranteed standard of excellence. We provide priority access to accredited clinics, tailored treatment plans, and financial support programs.
Discover the unique advantages of STEM Cell Treatment for your long-term health. Take a moment to complete the form with care, ensuring every required field is filled in so we can offer the most accurate guidance.
The medical and administrative teams expressly dissociate themselves from any form of advertising or promotional activity in relation to the Pro Bono Program, whether the support provided is partial or full.
Respect for patient dignity, privacy, and confidentiality remains a fundamental priority. Accordingly, no personal data, identifying information, or photographs of patients or of the parents of children with medical conditions will be published.
Any video or graphic materials displayed on this platform include only patients or families who:
Have not benefited from the Pro Bono Program;
Have benefited partially or fully from the Program, in collaboration with associations, sponsors, or through direct support provided by STEM Cell Vienna
This clarification is provided in the interest of transparency and to ensure a clear understanding of the context in which such materials were produced and published.